Although cannabis is still considered to have no medical use by the Drug Enforcement Administration, pharmaceutical companies continue to create medications that prove its efficacy against countless ailments. Cannabis Science, Inc. has developed two new pain relief patches that are specifically for patients with Diabetic Neuropathy nerve pain and Fibromyalgia.
Fibromyalgia is a medical condition in which the individual experiences chronic widespread pain and a higher, more painful response to pressure. Neuropathy damages or spreads disease to nerves and can have various painful effects depending on which nerves are affected. Now patients facing either of these ailments might find relief with the transdermal CBD patches created by Cannabis Science.
The transdermal pads are made with high potency cannabinoid (CBD) extract. The extract is released in a controlled fashion, which enters into the bloodstream through a medicated adhesive patch that is put on the skin. The CBD extract enters through the skin and into the central nervous system, which is how patients receive pain relief.
The Cannabis Science CEO, Raymond C. Dabney, confirmed that these developments are just the beginning for his company, according to www.biospace.com. “The development of these two new pharmaceutical medicinal applications are just the tip of the iceberg for what we see as the future of Cannabis Science,” Dabney said. “While we strive to increase our land capacity for growth and facilities to produce our own product to supply our scientists with proprietary materials to make these formulations, we are so busy researching more potential needs for cannabis-related medical applications and developing the methods for delivery of these medications.”
CBD is notorious for being one of the active ingredients in cannabis that leads to various healing properties from helping to reduce seizures to acting as an anti-inflammatory and pain reliever. One of its most attractive properties to many is that it does not have any psychoactive properties. As more states vote soon on allowing medical cannabis programs in their state, Cannabis Science only sees greater opportunity to help more patients.
“As more states nationwide legislate for the legalization of cannabis and cannabis derived medications, we here at Cannabis Science are focused on developing pharmaceutical formulations and applications to supply the huge growing demand expected over the coming few years,” Dabney said.